clinical trial · NCT07863193
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
Acne VulgarisDenifanstatPlacebo
brief summary
The purpose of this study is to evaluate the safety and efficacy of denifanstat compared with matching placebo in participants with moderate to severe acne vulgaris who are ≥12 years of age. After the 12-week treatment phase, a subset of approximately 530 participants will have the option to consent to an open-label extension phase for an additional 40 weeks of treatment.
started
Oct 1, 2026
primary completion
Aug 1, 2027
completion
Apr 1, 2028
last updated
Oct 29, 2026
official title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Design Trial to Evaluate the Safety and Efficacy of Denifanstat in Participants With Moderate to Severe Acne Vulgaris
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol